Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 27 of 5804
-
New shot could soothe tough eczema for teens and adults
Disease control Not yet recruitingRationale (What is the reason for this study?) Atopic dermatitis (AD) is a condition that makes the skin dry and itchy and is the most common skin condition that causes redness and irritation. The exact cause of AD is unclear but genetic and environmental factors are believed to…
Phase: PHASE3 • Sponsor: Shanghai Mabgeek Biotech.Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for Hard-to-Treat breast cancer: phase 3 trial launches
Disease control Not yet recruitingThe purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunot…
Phase: PHASE3 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Lung cancer trial seeks optimal immunotherapy schedule around surgery
Disease control Not yet recruitingThis is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and adjuvant immunotherapy using Toripalimab, in patien…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Kidney removal after immunotherapy may offer cure for select patients
⭐️ CURE ⭐️ Recruiting nowIn the current era of immune checkpoint inhibitors (ICI), the role and timing of nephrectomy remains unknown, particularly in cases of residual kidney disease after a major response at metastatic sites. In these cases, the rationale for a delayed nephrectomy is that it might achi…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 11:03 UTC
-
New hope for tough-to-treat myeloma: trial combines smart drugs to beat cancer
Disease control Recruiting nowThe Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an in…
Phase: PHASE2 • Sponsor: Multiple Myeloma Research Consortium • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Triple-Drug attack on aggressive leukemia shows promise in major trial
Disease control Not yet recruitingThis is a multicenter, randomized, controlled, open-label phase III trial evaluating the efficacy and safety of the VAG regimen (azacitidine, venetoclax, and gilteritinib) compared with standard 3+7 chemotherapy (cytarabine plus daunorubicin or idarubicin) combined with gilteriti…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Pregnancy shot may shield newborns from deadly RSV – major brazil trial launches
⭐️ VACCINE ⭐️ Not yet recruitingThe overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants…
Sponsor: Inova Medical • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:09 UTC
-
Stem cell shot during bypass aims to rebuild failing hearts
Disease control Recruiting nowThe purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure (NYHA Class III-IV)
Phase: PHASE3 • Sponsor: HELP Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New mRNA vaccine could stop lyme disease in its tracks
⭐️ VACCINE ⭐️ Recruiting nowThis clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to stop breast cancer return in High-Risk patients
Disease control Recruiting nowIn this clinical trial, the Sponsor plans to investigate whether patients with HR+/HER2- eBC identified during routine clinical assessments and treatments as having intermediate to high-risk (based on Oncotype DX® or similar tests and on response assessment to 2-6 weeks of preope…
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Shingles shot may shield seniors from heart attacks and dementia
Prevention Recruiting nowDAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults. Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes more common…
Phase: PHASE4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New hope for hemophilia a: phase 3 trial launches for Next-Gen bleed prevention
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a neck implant be the lifeline heart failure patients need?
Disease control ENROLLING_BY_INVITATIONThe purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated …
Phase: NA • Sponsor: CVRx, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough prostate cancer: BNT324 takes on chemo
Disease control Recruiting nowThis study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study …
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for hepatitis d: libevitug enters final testing phase
Disease control Recruiting nowThis is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Phase: PHASE3 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take on lupus nephritis
Disease control ENROLLING_BY_INVITATIONSystemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients. Currently, cell-based therapy has emerged as an innovative treatment approach f…
Phase: NA • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot aims to slash stroke risk by crushing cholesterol
Disease control Not yet recruitingThe Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C …
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Two-Pronged gene therapy takes on deadly brain tumors
Disease control Recruiting nowThe goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma. TGX-007 is a gene therapy drug delivered by a…
Phase: PHASE1, PHASE2 • Sponsor: Trogenix ltd • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for advanced breast cancer: experimental combo enters phase 3 trial
Disease control Recruiting nowThis trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast c…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Gene-Editing shot aims to fix rare lung and liver disease
Disease control Recruiting nowThis is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver dis…
Phase: PHASE1, PHASE2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC